Program
retlirafusp alfa
Also written as “SHR-1701”, “SHR-1701;BP102” and “SHR-A1811 and SHR-1701”.
Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Stomach Neoplasms · Neoplasm Metastasis · Nasopharyngeal Carcinoma · Pancreatic Neoplasms, led by Jiangsu HengRui Medicine.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Jiangsu HengRui Medicine | 206 open or running | phase 3since Jun 29, 2021 | Oct 14, 2018 | Jul 30, 2027phase 2 · NCT05503888 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 4 studies since Oct 14, 2018.
- Sep 28, 2020Phase 2 study in Carcinoma, Non-Small-Cell LungNCT04580498 · 107 enrolled · China
- Nov 2, 20202 phase 2 studiesNCT04624217, NCT04650633
- Jan 5, 2021Phase 2 study in Carcinoma, Non-Small-Cell LungNCT04699968
- Apr 19, 2021Phase 2 study in Advanced Solid TumorsNCT04856774 · 81 enrolled · China
- May 7, 2021Phase 2 study in Lung NeoplasmsNCT04884009 · 106 enrolled
- Jun 29, 2021Phase 3 study in Gastric or Gastroesophageal Junction CancerNCT04950322 · 737 enrolled · China
- Jul 16, 2021Phase 2 study in Advanced or Metastatic Non-squamous Non-small Cell Lung CancerNCT04974957 · 71 enrolled
- Aug 23, 2021Phase 2 study in Nasopharyngeal CarcinomaNCT05020925 · 30 enrolled · China
- Nov 9, 20212 phase 3 studiesNCT05149807, NCT05132413
- Jan 3, 2022Phase 1 study in Advanced Malignant TumorsNCT05198817 · 240 enrolled · China
- Mar 18, 2022Phase 2 study in Locally Advanced Rectal CancerNCT05300269 · 73 planned · China
- Aug 8, 2022Phase 2 study in RecurrenceNCT05503888 · 160 planned
- Jan 3, 2023Phase 2 study in HER2 Expression Gastric Cancer/Gastroesophageal Junction AdenocarcinomaNCT05671822 · 258 planned · China
- Sep 9, 2025Phase 2 study in Carcinoma, Non-Small-Cell LungNCT07175220 · 200 planned · China
Ahead
- Jul 30, 2027Primary completion: phase 2 study in RecurrenceNCT05503888
- Dec 2027Primary completion: phase 2 study in HER2 Expression Gastric Cancer/Gastroesophageal Junction AdenocarcinomaNCT05671822
- Oct 2028Primary completion: phase 2 study in Carcinoma, Non-Small-Cell LungNCT07175220
TargetBeta
“A bifunctional fusion protein composed of an anti-programmed death ligand 1 (PD-L1) monoclonal antibody bound, via the C-terminal ends of the Fc region, to the N-terminal-truncated extracellular domain (ECD) of human transforming growth factor beta (TGFbeta) receptor type II (TGFbetaRII), ”NCIt, by rule
Studies
All 20 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07175220Carcinoma, Non-Small-Cell Lung · China | 2 | Recruiting | Oct 2028 | 200 |
| NCT05671822HER2 Expression Gastric Cancer/Gastroesophageal Junction Adenocarcinoma · China | 2 | Recruiting | Dec 2027 | 258 |
| NCT05503888Recurrence | 2 | Not yet recruiting | Jul 30, 2027 | 160 |
| NCT05300269Locally Advanced Rectal Cancer · China | 2 | Recruiting | Jul 31, 2024 | 73 |
| NCT05198817Advanced Malignant Tumors · China | 1 | UNKNOWN | Jan 31, 2023 | 240 |
| NCT05132413Advanced or Metastatic Non-squamous Non-small-cell Lung Cancer | 3 | UNKNOWN | Dec 30, 2024 | 561 |
| NCT05149807Perioperative Treatment in Subjects With Locally Advanced Resectable Gastric Cancer or Gastroesophageal Junction Cancer · China | 3 | Terminated | Apr 3, 2024 | 81 |
| NCT05020925Nasopharyngeal Carcinoma · China | 2 | UNKNOWN | May 2022 | 30 |
| NCT04974957Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer | 2 | UNKNOWN | Feb 28, 2022 | 71 |
| NCT04950322Gastric or Gastroesophageal Junction Cancer · China | 3 | Active, not recruiting | May 20, 2024 | 737 |
| NCT04884009Lung Neoplasms | 2 | UNKNOWN | Dec 31, 2022 | 106 |
| NCT04856774Advanced Solid Tumors · China | 2 | Completed | Mar 30, 2024 | 81 |
| NCT04699968Carcinoma, Non-Small-Cell Lung | 2 | Withdrawn | Nov 15, 2021 | 0 |
| NCT04650633Squamous Cell Carcinoma of Head and Neck · China | 2 | UNKNOWN | Jan 2023 | 130 |
| NCT04624217Pancreatic Neoplasms · China | 2 | Completed | Sep 16, 2021 | 56 |
| NCT04580498Carcinoma, Non-Small-Cell Lung · China | 2 | Active, not recruiting | Jul 15, 2023 | 107 |
| NCT04282070Nasopharyngeal Carcinoma · China | 1 | UNKNOWN | Apr 16, 2022 | 91 |
| NCT04324814Advanced Solid Tumor · Australia | 1 | Completed | Feb 1, 2023 | 41 |
| NCT03774979Neoplasm Metastasis · China | 1 | UNKNOWN | Mar 2023 | 193 |
| NCT03710265Neoplasm Metastasis · China | 1 | UNKNOWN | Dec 31, 2022 | 206 |
How it is read
Names in the registry
- “SHR-1701”, 10 entries
- “SHR-1701;BP102”, 2 entries
- “SHR-A1811 and SHR-1701”, 1 entry
- “SHR-A181, SHR-1701, and capecitabine”, 1 entry
- “SHR2554; SHR-1701”, 1 entry
Codes read as this program: SHR1701.
Conditions, from the studies’ own filings
- Carcinoma, Non-Small-Cell Lung, 5 studies
- Stomach Neoplasms, 2 studies
- Neoplasm Metastasis, 2 studies
- Nasopharyngeal Carcinoma, 2 studies
- Pancreatic Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.